ACO-REALAcoramidis Use in ATTR Amyloidosis with Cardiomyopathy

Transthyretin Amyloid Cardiomyopathy, or ATTR-CM, is a condition where a protein called transthyretin misfolds and builds up in the heart muscle, causing the heart to become stiff and leading to heart failure. There are two types of ATTR-CM: one caused by a genetic mutation and another associated with aging. The condition is often diagnosed late because its symptoms can resemble other heart issues. Acoramidis is a new medication approved for treating ATTR-CM by stabilizing the transthyretin protein, preventing harmful deposits. This study, named ACO-REAL, aims to gather real-world evidence on how acoramidis works for patients in everyday medical practice. It is conducted across 20 European countries and will involve up to 2,000 adults with either form of ATTR-CM who are beginning treatment with acoramidis. In this observational study, researchers will not change how patients are treated. Instead, they will observe patients who are receiving acoramidis as part of their regular care. The study will collect detailed information about the patients, including their demographics and medical history, to understand who is receiving the medication. It will also track how the treatment affects heart function, the ability to perform daily activities, overall health, quality of life, and the use of healthcare services like hospital visits. Additionally, safety data will be gathered to monitor how often the medication is stopped or interrupted and why. This real-world data will help improve the management and treatment of ATTR-CM, offering insights that could enhance patient care.